Investor Contact:Paul Cox, Sage Therapeuticspaul.email@example.comMedia Contact:Dan Budwick, Pure Communicationsdan@purecommunicationsinc.com973-271-6085
CAMBRIDGE, Mass., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced that it will present at the Piper Jaffray 27 th Annual Healthcare Conference at 8:30 a.m. ET on Wednesday, December 2, 2015, in New York City. A live webcast of the presentation can be accessed on the investor page of SAGE's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on SAGE's website following the conference. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.